Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 287-292

  Lin, Po Han ^a,b,d   Lin, Ching Chan ^a,b   Yang, Hwai I ^b   Li, Long Yuan ^b   Bai, Li Yuan ^a   Chiu, Chang Fang ^a,b   Liao, Yu Min ^a   Lin, Chen Yuan ^a,b   Hsieh, Ching Yun ^a,b   Lin, Chien Yu ^a   Ho, Cheng Mao ^a   Yang, Shu Fen ^a   Peng, Ching Tien ^a   Tsai, Fuu Jen ^a,c   Yeh, Su Peng ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; FLT3

Indexed keywords

ACICLOVIR; ANTHRACYCLINE; BUSULFAN; CD135 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FLT3 GENE; GENDER; GENE DUPLICATION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HUMAN; IMMUNOPHENOTYPING; INFECTION; INFECTION PREVENTION; INTERNAL TANDEM DUPLICATION; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; TANDEM REPEAT SEQUENCES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84872932688     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.005     Document Type: Article

References (22)

1. Rowe J.M., Tallman MS How I treat acute myeloid leukemia. Blood 2010, 116:3147-3156.
2. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
3. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. cancer and leukemia group B. N Engl J Med 1994, 331:896-903.
4. Levi I., Grotto I., Yerushalmi R., et al. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res 2004, 28:605-612.
5. Pfirrmann M., Ehninger G., Thiede C., et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012, 13:207-214.
6. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
7. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial, The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
8. Schmid C., Labopin M., Nagler A., et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012, 119:1599-1606.
9. Hamadani M., Mohty M., Kharfan-Dabaja M.A. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control 2011, 18:237-245.
10. Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005, 103:1652-1658.
11. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
12. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
13. Meshinchi S., Stirewalt D.L., Alonzo T.A., et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 2008, 111:4930-4933.
14. Gale R.E., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005, 106:3658-3665.
15. Meshinchi S., Arceci R.J., Sanders J.E., et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006, 108:400-401.
16. Gale R.E., Hills R., Wheatley K., et al. Response: allogeneic stem cell transplantation and FLT3/ITD status in AML. Blood 2006, 108:400-401.
17. Bornhauser M., Illmer T., Schaich M., et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007, 109:2264-2265. author reply 2265.
18. DeZern A.E., Sung A., Kim S., et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011, 17:1404-1409.
19. Brunet S., Labopin M., Esteve J., et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012, 30:735-741.
20. Yanada M., Matsuo K., Suzuki T., et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005, 19:1345-1349.
21. Smith C.C., Wang Q., Chin C.S., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
22. Stone R.M., Fischer T., Paquette R., et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012, 26:2061-2068.